Journal article
Gastrointestinal Bleeding With Edoxaban Versus Warfarin
Abstract
BACKGROUND: The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction) compared higher-dose edoxaban regimen (HD-ER) and lower-dose edoxaban regimen with well-managed warfarin in 21 105 patients with atrial fibrillation. The risk factors and clinical impact of gastrointestinal bleeding (GIB) in this trial have not been described in detail.
METHODS AND …
Authors
Aisenberg J; Chatterjee-Murphy P; Friedman Flack K; Weitz JI; Ruff CT; Nordio F; Mercuri MF; Choi Y; Antman EM; Braunwald E
Journal
Circulation Cardiovascular Quality and Outcomes, Vol. 11, No. 5,
Publisher
Wolters Kluwer
Publication Date
May 2018
DOI
10.1161/circoutcomes.117.003998
ISSN
1941-7713
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAnticoagulantsAtrial FibrillationBlood CoagulationDose-Response Relationship, DrugDrug MonitoringFactor Xa InhibitorsFemaleGastrointestinal HemorrhageHumansInternational Normalized RatioMaleMiddle AgedPyridinesRandomized Controlled Trials as TopicRetrospective StudiesRisk AssessmentRisk FactorsThiazolesTime FactorsTreatment OutcomeWarfarin